We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00626249
First Posted: February 29, 2008
Last Update Posted: December 17, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mannkind Corporation
  Purpose
24 diabetics with mild & moderate renal disease and 12 diabetics without renal disease. One screening, one dosing & one follow-up visit with Technosphere® Inhalation Powder given at Visit 2 via MedTone® Inhaler and PK testing at 26 designated time points

Condition Intervention Phase
Mild Nephropathy Moderate Nephropathy Diabetes Mellitus Drug: Technosphere Inhalation Powder Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With Either Mild or Moderate Chronic Kidney Disease vs. Matched Subjects Without Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by Mannkind Corporation:

Primary Outcome Measures:
  • Differences in exposure to fumaryl diketopiperazine (FDKP) [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Additional safety parameters [ Time Frame: 14 days ]

Enrollment: 36
Study Start Date: August 2007
Study Completion Date: October 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: T Inhalation powder in diabetic subjs w/ normal renal func
T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
Drug: Technosphere Inhalation Powder
Technosphere Inhalation Powder
Experimental: T Inhalation powder diabetic subj w/mild or moderate nephrop
T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
Drug: Technosphere Inhalation Powder
Technosphere Inhalation Powder

Detailed Description:
This Phase 1, single-dose trial is being conducted to determine if nephropathy affects the way the kidneys eliminate the byproducts of Technosphere® Inhalation Powder as compared to kidneys free of disease. This trial will test the safety, tolerability and pharmacokinetics of the study medication. The trial consists of a screening, dosing and a follow-up visit. Single dose administration of Technosphere® Inhalation Powder occurs at the dosing visit. (V2) with serum and urine PK testing .
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Non-smoking males and females, = 18 and = 80 years with a BMI of = 37 kg/m2
  • Type 1 or type 2 diabetic
  • Subjects with mild or moderate DNP and subjects with normal renal function, based on GFR rate and albuminuria
  • Normal pulmonary function and performance based on PFTs

Exclusion Criteria:

  • No history of COPD, asthma, or active respiratory infection; must be able to perform PFTs
  • No dose and/or formulation changes within the preceding 6 weeks for any concomitant medications
  • No clinically significant major organ/systemic disease
  • No previous or current chemotherapy or radiation therapy that may result in pulmonary toxicity
  • No clinically significant abnormalities on screening laboratory evaluation, except abnormal laboratory renal parameters in subjects with DNP
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626249


Locations
United States, Minnesota
Davita Clinical Research
Minneapolis, Minnesota, United States, 55404
United States, Nebraska
Qualia Clinical Research
Omaha, Nebraska, United States, 68154
United States, Texas
Diabetes & Glandular Disease Research Assoc PA
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Mannkind Corporation
Investigators
Study Director: Anders Boss Mannkind Corporation
  More Information

Responsible Party: Mannkind Corporation
ClinicalTrials.gov Identifier: NCT00626249     History of Changes
Other Study ID Numbers: MKC-T-017
First Submitted: February 21, 2008
First Posted: February 29, 2008
Last Update Posted: December 17, 2013
Last Verified: December 2013

Keywords provided by Mannkind Corporation:
Nephropathy
Kidney Disease
Diabetic
Renal
Diabetics

Additional relevant MeSH terms:
Diabetes Mellitus
Kidney Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases